Navigation Links
UC Davis investigators achieve important step toward treating Huntington's disease
Date:1/19/2012

(SACRAMENTO, Calif.) A team of researchers at the UC Davis Institute for Regenerative Cures has developed a technique for using stem cells to deliver therapy that specifically targets the genetic abnormality found in Huntington's disease, a hereditary brain disorder that causes progressive uncontrolled movements, dementia and death. The findings, now available online in the journal Molecular and Cellular Neuroscience, suggest a promising approach that might block the disease from advancing.

"For the first time, we have been able to successfully deliver inhibitory RNA sequences from stem cells directly into neurons, significantly decreasing the synthesis of the abnormal huntingtin protein," said Jan A. Nolta, principal investigator of the study and director of the UC Davis stem cell program and the UC Davis Institute for Regenerative Cures. "Our team has made a breakthrough that gives families affected by this disease hope that genetic therapy may one day become a reality."

Huntington's disease can be managed with medications, but currently there are no treatments for the physical, mental and behavioral decline of its victims. Nolta and other experts think the best chance to halt the disease's progression will be to reduce or eliminate the mutant huntingtin (htt) protein found in the neurons of those with the disease. RNA interference (RNAi) technology has been shown to be highly effective at reducing htt protein levels and reversing disease symptoms in mouse models.

"Our challenge with RNA interference technology is to figure out how to deliver it into the human brain in a sustained, safe and effective manner," said Nolta, whose lab recently received funding from the California Institute for Regenerative Medicine to develop an RNAi delivery system for Huntington's disease. "We're exploring how to use human stem cells to create RNAi production factories within the brain."

Huntington's disease affects more than a q
'/>"/>

Contact: Charles Casey
charles.casey@ucdmc.ucdavis.edu
916-734-9048
University of California - Davis Health System
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UC Davis researcher develops model to foster new drug development to treat pain and epilepsy
2. UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento
3. UC Davis researchers discover complexities of DNA repair
4. UC Davis neurosurgeons use adult stem cells to grow neck vertebrae
5. UC Davis researchers find disease-causing fat cells in those with metabolic syndrome
6. 2 UC Davis plant biologists named as HHMI-GBMF investigators
7. NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials
8. AAAS news briefs from UC Davis
9. UC Davis energy experts to help US Navy get greener
10. Death in the bat caves: UC Davis experts call for action against fast-moving disease
11. UC Davis study shows plants moved downhill, not up, in warming world
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/8/2015)... NEW YORK , July 8, 2015  BD ... announced BD & Guidepoint Mentor, a new ... to Guidepoint,s expert network services. BD ... technologies to improve healthcare delivery and outcomes and, with ... start-up entrepreneur will be able to directly engage with ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... CA--A team of marine scientists has found that toxin-producing algae ... common in the open ocean, where the addition of iron ... the harmful algae. The new findings, reported this week in ... add to concerns about proposals to use iron fertilization of ...
... Medicine researchers at the Robert H. Lurie Comprehensive Cancer Center ... made from a chemical in soy could prevent the movement ... the body. These findings will be presented at the ... Prevention Research Conference. Genistein, a natural chemical found in ...
... 8, 2010 A study published in the November ... the Alzheimer,s Association suggests that taking docosahexaenoic acid ... with mild cognitive impairments. This is promising news ... to maintain memory and support overall cognitive health. The ...
Cached Biology News:Iron stimulates blooms of toxin-producing algae in open ocean, study finds 2Soy may stop prostate cancer spread 2DHA improves memory and cognitive function in older adults 2
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... ... 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers ... drug/device combinations. The current system received a score of 0 (range -10 to +10) ... (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and ...
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ formalized ... specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and ... PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... N.Y. A new technique for growing single-crystal ... enable the development of smaller, more powerful heat ... , Researchers at Rensselaer Polytechnic Institute have discovered ... up of two single crystals using a biomolecular ...
... In conjunction with,CorVel Corporation,s (Nasdaq: CRVL ) quarterly earnings release, CorVel ... on Tuesday, August 5th at 11:30 am Eastern Time., Event: ... by: Dan Starck, President and CEO ... Date: 11:30 am Eastern Time, Tuesday, ...
... July 17 Researchers at Fred Hutchinson Cancer,Research ... from the,National Human Genome Research Institute to better ... The Hutchinson Center is one of,four U.S. research ... this effort., The Hutchinson Center project, led ...
Cached Biology Technology:'Nanosculpture' could enable new types of heat pumps and energy converters 2CorVel Corporation Announces Earnings Release Webcast 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 3
Fetal Calf Serum Replacement (Bistec) serum...
NEWBORN CALF SERUM AND PLASMA...
... reagent for Virus isolation ... unique water insoluble Elastomeric ... and chaotropes; Engineered to ... viruses while preserving infectivity; ...
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
Biology Products: